Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 9/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17461866 | 0.95 | NPC1 (0.64) | NPC1HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL16120023 | 0.90 | NPC1 (0.62) | NPC1HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL29643244 | 0.84 | NPC1 (0.80) | NPC1HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL28266234 | 0.84 | NPC1 (0.80) | NPC1HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL16098831 | 0.84 | NPC1 (0.67) | NPC1HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL17461821 | 0.81 | NPC1 (0.52) | NPC1HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL17461841 | 0.80 | HPGD (0.57) | NPC1HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL17461828 | 0.79 | HPGD (0.50) | NPC1HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL16120150 | 0.78 | HPGD (0.73) | NPC1HPGDALDH1A1KDM4ELMNA | |
| SCHEMBL17461867 | 0.78 | HPGD (0.51) | NPC1HPGDALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | AR, KLK3, BRDT | NPC1 2157/4885HPGD 166/4885ALDH1A1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.